Lymphoid cancer
2 papers
- Human trial2
Latest
1 in 12 monthsmedRxiv
Potential five-year life years associated with stage IV reductions in NHS Galleri Trial
Preprint: trial in peopleInterventions
The Lancet Oncology
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Non-randomised trial in 55 peopleSenolytics